Mylan Issues Nationwide Recall for Contaminated Ulcer Medication

Mylan (NASDAQ:MYL) announced today that its American-based business issued a voluntary nationwide recall for its ulcer medication after discovering trace amounts of carcinogens in some of its old batches. Three different lots of nizatidine capsules, including both the 150mg and 300mg dose variants, were found to contain small amounts of N-Nitrosodimethylamine (NDMA), and the company has since issued a voluntary recall for all capsules suspected to be contaminated.